Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation

Palbociclib and ribociclib are indicated in the first-line treatment of hormonal-receptor-positive HER-2 negative (HR+/HER-2 negative) advanced breast cancer. Despite their clinical benefit, they can increase healthcare expenditure. Yet, there are no comparative pharmacoeconomic evaluations for them...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Ziftawi, Nour Hisham, Alam, Mohammed Fasihul, Elazzazy, Shereen, Shafie, Asrul Akmal, Hamad, Anas, Mohamed Ibrahim, Mohamed Izham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9819837/
https://www.ncbi.nlm.nih.gov/pubmed/36612831
http://dx.doi.org/10.3390/ijerph20010512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9819837/
https://www.ncbi.nlm.nih.gov/pubmed/36612831
http://dx.doi.org/10.3390/ijerph20010512

Ejemplares similares